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Background: The Decipher test measures expression of 22 RNA biomarkers associated
with aggressive prostate cancer used to improve risk stratification of patients to help
guide management. To date, Decipher's genomic classification has not been extensively
correlated with specific histologic growth patterns in prostatic adenocarcinoma. With a
growing understanding of the clinical aggressiveness associated with cribriform growth
pattern (CF), intraductal carcinoma (IDC), and percent Gleason pattern 4 (G4%), we
sought to determine if their presence was associated with an increased genomic risk as
measured by the Decipher assay.
Design: Clinical use of the Decipher assay was performed on the highest Gleason
score (GS) tumor nodule of prostatectomy specimens from a prospective cohort of 48
patients, with GS varying from 7 through 9 to help guide clinical risk stratification.
The tumors were reviewed for CF, IDC, and G4%, which were then compared to the
Decipher score (0‐1) and risk stratification (high vs not high).
Results: The presence of CF/IDC was significantly associated with Decipher risk
score (P = .007), with a high‐risk Decipher score in 22% vs 56% of patients without or
with CF/IDC. On binary logistic regression analysis, G4% (odds ratio [OR] 1.04 per
percent increase [95% confidence interval [CI], 1.02‐1.06]; P = .0004) and CF
predominant (OR, 9.60 [95%CI, 1.48‐62.16]; P = .02) were significantly associated
with a high‐risk GC score. IDC did not reach significance (OR, 1.92 [95%CI,
0.65‐5.67]; P = .24).
Conclusions: Our findings add to an expanding knowledge base that supports G4%
and CF/IDC as molecularly unique and clinically relevant features in prostatic
adenocarcinoma. These histologic features should be standardly reported as they are
associated with more aggressive prostate cancer. Future work should determine the
independent information of these histologic findings that are relative to genomic
assessment on long‐term outcomes.
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1 | INTRODUCTION
The management of localized prostate cancer is grounded in risk
stratification. This generally includes common prognostic variables,
such as baseline serum prostate‐specific antigen (PSA), tumor stage,
Gleason score (GS), and percent positive biopsy cores. These are the
key variables that comprise clinically used multivariable models, such
as the National Comprehensive Cancer Network (NCCN)1 or the
cancer of the prostate risk assessment (CAPRA)2 risk groups.
However, there is additional histologic data readily available that
has independent prognostic value, and yet is often not incorporated
into these models.
In one of our previous studies, Cole et al3 showed that the percent
of Gleason pattern 4 (G4%) is predictive of both adverse pathology (at
time of radical prostatectomy [RP]) and biochemical recurrence at
more specific G4% thresholds (ie 1%‐10% G4 vs 20%‐30% G4) within
Gleason 3 + 4 disease. Moreover, cribriform growth pattern (CF),
classified as G4%, has been demonstrated to be an independent risk
factor for metastasis and disease specific death, and the presence of
CF combined with G4% outperforms G4% in predicting biochemical
recurrence free‐survival.4-7 Similarly, the presence of intraductal
carcinoma (IDC‐P) at the time of biopsy or prostatectomy has also
been associated with poor outcomes, including biochemical recur-
rence, metastatic disease, and prostate cancer‐specific mortality.4,8-11
Due to the morphologic overlap between invasive CF and IDC‐P, some
studies have grouped both patterns into a single group (presence of CF
and/or IDC‐P), which also carries prognostic value.4,9
In parallel to the identification of histologic features that are
associated with prognostic groups, there are now several commercially
available prognostic gene expression‐based tests that assess prostate
cancer tissue (eg, Decipher,12 Oncotype Dx,13 Prolaris14). Of these, the
Decipher test (GenomeDX Biosciences) is relatively commonly used
after RP and measures the expression of 22 RNA biomarkers
associated with aggressive prostate cancer. These biomarkers are
comprised of coding and noncoding RNA in or near genes associated
with aggressive prostate cancer. Attributed functions of these genes
include cellular proliferation, differentiation, cell cycle progression, cell
structure and adhesion, immune response, and yet‐unknown functions;
seven of these genes are androgen‐regulated.12 This test issues a score
and risk categorization validated to predict 5‐year metastatic risk and
10‐year prostate cancer‐specific mortality. Additionally, Decipher has
been shown in a recent meta‐analysis to independently predict
metastatic development when adjusting for patient age, tumor stage,
nodal stage, Gleason grade group, margin status, and adjuvant or
salvage therapies.15 Furthermore, the addition of Decipher to NCCN or
CAPRA significantly improves the ability to identify which patients will
subsequently develop metastatic disease.16 For these reasons, Deci-
pher testing has recently been included in NCCN guidelines for
prostate cancer in specific clinical scenarios.1 However, to date,
Decipher's genomic classification has not been extensively correlated
with histologic features beyond GS.17 Thus, we sought to determine if
the presence of CF, IDC, or G4% are associated with an increased
genomic risk score in patients with prostate cancer.
2 | MATERIALS AND METHODS
2.1 | Study cohort
All patients were part of our prostate cancer registry maintained
through the Michigan Prostate Specialized Programs of Research
Excellence (SPORE), a collaborative and interdisciplinary translational
research effort; through this translational research program, the
National Cancer Institute (NCI) brings together the experience and
expertise of research scientists from across the nation to collaborate in
interdisciplinary translational prostate cancer research. All patients
included in this study underwent RP and lymph node dissection for
clinically localized prostate cancer followed by clinical use of the
Decipher test between 2016 to 2018. Use of the Decipher test was
considered in cases with pT3 disease and/or positive surgical margins
and ultimately decided upon via clinician preference and patient
consent at postoperative follow‐up. Patients were included for the
current analysis if their RP pathology had a component of G4% along
with available slides to review to quantify the presence of CF, IDC, and
G4%. No patients underwent neoadjuvant therapy, including androgen
deprivation, before RP. The study was reviewed and approved by the
University of Michigan Institutional Review Board.
2.2 | Histopathologic review
Two reviewers, including one pathology resident (AST) and one
genitourinary pathologist (RM), reviewed whole‐mount prostatectomy
slides from the cases on which Decipher testing was ordered. The
tumors were assessed for CF pattern (including both dense and loose
cribriform growth) on a 0 to 2 scale (0 or no CF = not present, 1 or CF
minor = present in less than 50% of the Gleason 4 component, 2 or
CF predominant= present in more than 50% of the Gleason 4
component). The presence of IDC was similarly noted as not present,
present, or a predominant feature. The percentage of G4% was
estimated and CF and IDC were scored based on the index tumor
nodule within the whole‐mount slide representing the block sent for
Decipher testing (consistent with the highest GS); all slides from each
case were reviewed to confirm that the block sent for testing was
indeed representative of the index tumor/highest grade nodule. This
cohort represents a real time assessment of patients with prostate
cancer for Decipher analyses; hence, formalin‐fixed paraffin‐embedded
(FFPE) tissue corresponding to the index tumor of area was submitted
for Decipher testing; serial consecutive sections were not available to
perform immunohistochemistry for basal cell markers to discern
CF from IDC‐P, which were distinguished upon morphologic basis only.
2.3 | Specimen selection for Decipher testing
FFPE tissue blocks were selected from each case after review of
whole‐mount hematoxylin and eosin stained slides from the
prostatectomy specimen. According to testing recommendations,
the block felt to be best representative of the most prognostic (ie,
highest grade) tumor nodule was submitted for analysis for Decipher
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testing. For example, if one slide portrayed GS 7 carcinoma with 10%
G4% and another slide showed G4% of 40%, the latter block was
submitted. Similarly, if one block demonstrated tertiary Gleason
pattern 5, it was selected against other blocks that did not
demonstrate a tertiary high‐grade pattern.
2.4 | Calculation of Decipher score and risk
categorization (Decipher assay)
Described in greater depth in prior work, the Decipher assay
(GenomeDX) measures the expression of 22 RNA biomarkers and
delivers a continuous score (between 0 and 1) for which higher scores
indicate an increased risk of clinical metastasis and cancer related
mortality.12 The score is reported along with a validated categorization
as “low risk” (<0.45), “intermediate risk” (0.45‐0.60), and “high‐risk”
(>0.60).18 In a recent patient‐level meta‐analysis, patients in
the low, intermediate, and high‐risk categories had a 5‐year
incidence of metastasis of 2.4%, 5.8%, and 15.2%, respectively, and
a 10‐year incidence of metastasis of 5.5%, 15.0%, and 26.7%,
respectively.15
2.5 | Statistical analyses
Statistical significance for risk category and scores were determined
by χ2 contingency analysis and Fisher's t test, respectively. Binary
logistic regression analysis was performed to determine the associa-
tion of clinical and pathologic features with the probability of having
a high Decipher score (vs a low or intermediate score). Given the
limited number of patients, a multivariable analysis was deemed to
not be advised given the high probability of overfitting the model.
Previous work4,9 has acknowledged the morphologic overlap
between CF invasive carcinoma and IDC by combining them in a
single category for analysis, so we also sought to establish if CF
pattern and/or IDC were significantly associated with Decipher risk
categorization. We also analyzed if CF pattern and IDC alone were
associated with higher risk stratification by Decipher. Finally, the
group of GS 3 + 4 adenocarcinoma was separated into groups of G4%
at a potentially clinically relevant threshold of 15% (less than 15%
and greater than or equal to 15%) based on outcome differences
between 1% to 10% G4 vs 20% to 30% G4 in Cole et al3; risk
categorization and Decipher scores were analyzed for patients with
G4% above and below this threshold.
3 | RESULTS
3.1 | Clinical and pathological characteristics of the
study cohort
The cohort of 48 patients selected by clinicians for Decipher testing is
characterized in Table 1. The average age of patients was 63 years
(range, 47‐73 years). The median baseline PSA was 7.3 ng/mL. Gleason
grade groups are represented as follows: group 2 (n = 26, 54%),
3 (n = 16, 33%), 4 (n = 2, 4%), and 5 (n = 4, 8%). Cribriform growth was
observed in 38 (79%) cases and IDC was observed in 15 (31%).
Pathologic staging demonstrated extraprostatic extension in 40 (83%)
cases and seminal vesicle invasion in 10 (21%) cases. Positive surgical
margins were demonstrated in 17 (35.4%) cases. 12 (25%) tumors were
anterior dominant, 11 (23%) involved the transition zone, and 25 (52%)
were exclusively peripheral zone. All patients had clinical and
pathologic node negative disease.
The median duration of follow‐up after RP for the cohort was 291
days (range 39‐571 days), at which point 7 patients (15.6%) had started
adjuvant radiation therapy, 40 (83.3%) were on a surveillance protocol,
and 1 (2.1%) patient had received salvage radiation therapy.
3.2 | Correlation of Decipher score and
categorization with routine clinicopathologic features
Baseline PSA was strongly correlated with the Decipher score
(R2 = 0.97; Figure 1A). Increases in Gleason grade group were
TABLE 1 Patient and tumor characteristics
N %
Age, y
Median (range) 63 47‐73
Baseline PSA (ng/mL)







Extracapsular extension 40 83













Peripheral zone 25 52
Involving transition zone 11 23
Anterior zone 12 25
Decipher score




Note: All patients had clinical and pathologic node negative disease.
Abbreviation: CAPRA, cancer of the prostate risk assessment.
aLocation of the sample sent for Decipher testing.
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correlated to a high Decipher score with an odds ratio of 4.78 (95%
confidence interval [CI], 1.58‐14.45; P = .01; Figure 1B). Pathologic
stage also increased Decipher categorization as high‐risk, with
particular significance of pT3b disease when compared to pT2 disease
(P = .008; Figure 1C). These results are summarized in Table 2.
3.3 | Correlation of CF and IDC to decipher results
The presence and predominance of cribriform growth increased high‐
risk categorization by Decipher (Figure 2A); when compared to
absent CF, present but not predominant CF nonsignificantly
increased Decipher high‐risk categorization (odds ratio [OR]= 3.64
[95%CI, 0.62‐21.36]; P = .15) and predominant CF significantly
increased high‐risk categorization (OR= 9.60 [95%CI, 1.48‐
62.16]; P = .02). The presence of IDC was nonsignificantly associated
with increased high‐risk Decipher (OR, 1.92 [95%CI, 0.65‐
5.67]; P = .24; Figure 2B). Specifically, within Gleason 3 + 4 (grade
group 2) disease, risk categorization by Decipher significantly
increased with the presence of cribriform growth (P = .037). The
presence of CF and/or IDC compared to neither pattern being
present (Figure 2C) was nonsignificantly associated with increased
high‐risk categorization (OR= 4.53 [95%CI, 0.83‐24.65]; P = .08) but
significantly associated with increased median Decipher risk score
(P = .007).
3.4 | Correlation of percent G4% to genomic risk
Among grade groups 2 through 4, the percent of G4% had a modest
correlation to Decipher score (R2= 0.2316; Figure 1D). However, for
each percentage point increase in G4% there was a 4% increase in
the odds of harboring a Decipher high‐risk score (OR, 1.04 [95%CI,
1.02‐1.06]; P = .0004). GS 3 + 4 cancer (grade group 2) with greater
than or equal to 15% G4 was associated with higher Decipher risk
than GS 3 + 4 cancer with less than 15% G4 (P = .019).
4 | DISCUSSION
In this study, the presence of CF and G4% were associated with
increased Decipher genomic risk. The association with cribriform
growth was significant when all cases were analyzed as well as when
only GS 3 + 4 = 7 cases were assessed. When cases were grouped by
presence or absence of IDC, no statistically significant association
was observed, which may be due to the limited number of cases with
IDC present given the OR estimate was over 1.0. In contrast, this
finding suggests that CF may carry more prognostic clinical relevance
than IDC, and may be a stronger histologic correlate of an aggressive
genomic signature in patients with prostate cancer. In the presence
of CF and/or IDC, there was a nonsignificant trend toward higher
Decipher risk categorization, supporting, albeit inconclusively, the
F IGURE 1 Decipher scores plotted against baseline PSA (A), histologic grade group (B), pathologic T‐stage (C), and percent Gleason pattern
4 (D). Decipher scores from 0 to 0.45 (shaded green), 0.45 to 0.6 (shaded white), and 0.6 to 1.0 (shaded red), are respectively considered low,
intermediate, and high‐risk. Black horizontal bar represents the median value. PSA, prostate‐specific antigen
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TABLE 2 Univariable analysis of covariables associated with decipher high‐risk
95%CI
Variable Odds ratio Lower Upper P value
Grade group ordinal 4.78 1.58 14.45 .01
%GP4 continuous 1.04 1.02 1.06 .0004
Max Size of tumor continuous 1.07 0.51 2.24 .87
pT‐stage
pT2 Reference
pT3a 6.562 0.72 59.85 .095
pT3b 56 2.93 1071.64 .008
Cribriform architecture (CF)
Absent Reference
Present 3.64 0.62 21.36 .15
Predominant 9.60 1.48 62.16 .02
Intraductal carcinoma (IDC) present vs absent 1.92 0.65 5.67 .24
CF and/or IDC present vs absent 4.53 0.83 24.65 .08
Abbreviation: CI, confidence interval.
F IGURE 2 Decipher scores with cases grouped by (A) the presence/predominance of cribriform growth, (B), the presence/predominance of
intraductal growth, and (C) the presence of CF and/or IDC vs both patterns absent. Decipher scores from 0 to 0.45 (shaded green), 0.45 to 0.6
(shaded white), and 0.6 to 1.0 (shaded red), are respectively considered low, intermediate, and high‐risk. Black horizontal bar represents the
median value. CF, cribriform; IDC, intraductal carcinoma
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idea that these features have some prognostic connotation as a
grouped category.
The prognostic importance of cribriform growth is further
reinforced by our data demonstrating a difference in Decipher risk
between patients with no cribriform growth, cribriform growth
comprising less than 50% of G4% disease, and cribriform
growth comprising 50% or greater of G4% disease. The volume of
prostatic adenocarcinoma with CF and its predominance within
G4% components may have clinically relevant importance that could
encourage its use in routine pathology reporting after further
investigation.
In addition, our study suggests that the specific percentage of
G4% in Gleason 3 + 4 = 7 cancer may have more prognostic impact
than previously understood. Using a threshold of 15%, we found GS
3 + 4 cancer with greater than or equal to 15% G4% to be associated
with higher Decipher risk than GS 3 + 4 cancer with less than 15%
G4% (P = .019). These results in addition to other work demonstrat-
ing the importance of similar thresholds of G4% percentage in biopsy
specimens3 raise the potential importance of G4% in explaining the
molecular/clinical heterogeneity among GS 3 + 4 carcinoma. While
there is no single accepted G4% threshold, GS 3 + 4 cancer with G4%
of less than 15% may have clinical and biological behavior closer to
GS 6 than GS 7 disease. Thus, the G4% in RP specimens of GS 3 + 4
may be a relevant component to include in pathology reports.
Our results do reflect a population from real world, clinical use of
the Decipher assay, indicating utility in a cohort of patients derived
from day to day practice. A limitation of our study, on the other hand,
includes ascertainment bias due to the method of accruing patients
who were thought to benefit from genomic risk information for clinical
decision making with respect to adjuvant therapy after RP. Our patient
population is targeted to real world practice and does not include many
patients with the extremes of low‐ and high‐stage and grade disease for
whom the decision for adjuvant therapy could be made without
ancillary genomic information. While pathologic limitations such as
interobserver variability in the recognition of or in distinguishing CF
from IDC may affect generalizability, cribriform growth is a relatively
easily recognized feature in prostatic adenocarcinoma for genitourinary
and general surgical pathologists alike. Finally, our inability to oversee
the specific area of tumor processed during Decipher testing limits
definitive conclusions regarding genomic risk within specific histologic
areas; however, given that the predominance of CF was observed to
affect a validated clinical genomic risk assessment tool, we add to the
body of literature that CF‐containing tumors do confer increased
clinical risk. Based on our results, routine histopathologic assessment
does not supplant the need for Decipher testing when recommended,
as some tumors with no CF or IDC were classified as high genomic risk
by Decipher. Rather, recognition and reporting of CF and IDC may add
complementary prognostic value to molecular testing or act as a
correlate to risk stratification in settings in which molecular testing is
limited or not possible. Additional work with a larger cohort may
further elucidate this potential benefit.
A larger scale study powered for multivariate analysis across GSs
would be beneficial to further assess the independent and grouped
effects of CF, IDC, and % G4% on genomic risk while controlling for
other clinicopathologic factors. Additional samples would also
improve the ability to discern the association between Decipher risk
and cribriform vs IDC. Additional work should focus on long‐term
follow‐up of this or similar cohorts to assess if certain histopathologic
variables are associated with mortality or metastasis specifically in
cases with high (or low) genomic risk.
In summary, our findings add to an expanding knowledge base
that supports CF as a unique and clinically relevant pattern of
prostatic adenocarcinoma. Based on Decipher assessment alone,
CF should be considered an indication of biologically aggressive
disease, especially among clinically heterogeneous groups of GS 3 + 4
(Gleason grade group 2) cancers. CF and IDC should be considered
for inclusion in templated histopathologic reporting, and may be
considered in future revisions of grade group categorization. More-
over, reporting the percentage of G4% in RP specimens can convey
clinically meaningful information to urologists and radiation oncol-
ogists, and a threshold of 15% G4% may carry prognostic importance.
This and future work may aid in increasing the prognostic value of
pathology reporting, improving selection of patients for genomic
testing, and optimizing information available for shared decision
making in clinical decisions about treatment options.
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